Decernotinib (類風濕性關節炎治療藥) - 2023年前的預測與市場分析
Decernotinib (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 84 Pages
|Decernotinib (類風濕性關節炎治療藥) - 2023年前的預測與市場分析 Decernotinib (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023|
|出版日期: 2014年12月31日||內容資訊: 英文 84 Pages||
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.
Decernotinib is a Phase III-ready JAK3 inhibitor being developed by Vertex for the treatment of active RA. As an oral therapy, it is expected to be administered as a monotherapy once or twice daily at a dosage of 50-200mg per day in patients who have had an inadequate response to MTX (or other csDMARDs) or one or more biologic agents.